Our faculty continue their discussion about clinical trials of HER3-directed therapies with a look at treatment-related adverse events and how to manage them.

Visit www.morningcommutepodcast.com/HER3Agnostic3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

In this episode our faculty take a look at the clinical trial data on HER3-directed therapies for breast and lung cancer.

Visit www.morningcommutepodcast.com/HER3Agnostic2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

In this episode, our faculty discuss the widespread expression of human epidermal growth factor receptor 3 (HER3) across tumor types and why clinicians should have HER3 on their radar.

Visit www.morningcommutepodcast.com/HER3Agnostic1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

In this episode our faculty take a look at the ins and outs of molecular testing in patients with HR+ positive breast cancer.

Visit www.morningcommutepodcast.com/HRPositiveBreast3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

In this podcast, our faculty take a look at some of the clinical data behind the newer treatment strategies for HR-positive breast cancer as well as how to address and manage some associated adverse events.

Visit www.morningcommutepodcast.com/HRPositiveBreast2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

In this podcast, our faculty discuss some newer treatment approaches for patients with HR-positive breast cancer including PI3K inhibition, AKT inhibition, and oral selective estrogen receptor down regulators.

Visit www.morningcommutepodcast.com/HRPositiveBreast1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

FLT3-inhibitors, such as quizartinib, are changing the treatment paradigm for AML, in this podcast, our faculty take a look at the drug class, how they are used in AML, and how to manage any treatment-related adverse events.

Visit www.morningcommutepodcast.com/aml4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

The treatment paradigm for the treatment of AML is changing. In this podcast, our faculty discuss quizartinib and the QuANTUM-First trial. 

Visit www.morningcommutepodcast.com/aml3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.